Liang Y.-F.,Guizhou Yi Bai Pharmaceutical Co. |
Sui D.-H.,Guizhou Yi Bai Pharmaceutical Co. |
Cheng Y.,Lung Cancer Medical Center
Chinese Journal of New Drugs | Year: 2014
Lobaplatin is a category I new antitumor drug with independent intellectual property rights. Compared with the cisplatin-based international standard regimens, a large number of clinical studies have shown that lobaplatin-based regimens have similar efficacy and better safety and tolerability. Especially it is suitable for old and weak patients, and can be used as a first-line therapy. Secondly, for the relapsed small cell lung cancer that failed to respond to the first-line treatment EP or EC regimens, IL regimen also has definite efficacy and good tolerability. It has been demonstrated that lobaplatin-based regimens have become the new treatment option of small cell lung cancer, but remain to be further studied to optimize clinical rational drug use.